What is the projected market valuation for the Hospital and Nursing Home Probiotic Market in 2035?

The projected market valuation for the Hospital and Nursing Home Probiotic Market in 2035 is 7.226 USD Billion. Read More

What was the market valuation for the Hospital and Nursing Home Probiotic Market in 2024?

The overall market valuation for the Hospital and Nursing Home Probiotic Market was 2.939 USD Billion in 2024. Read More

What is the expected CAGR for the Hospital and Nursing Home Probiotic Market from 2025 to 2035?

The expected CAGR for the Hospital and Nursing Home Probiotic Market during the forecast period 2025 - 2035 is 8.52%. Read More

Which companies are considered key players in the Hospital and Nursing Home Probiotic Market?

Key players in the market include Danone, Nestle, Procter & Gamble, Kerry Group, Chr. Hansen, Lactalis Ingredients, Synlogic, BioCare Copenhagen, and ProbioFerm. Read More

What are the projected revenues for probiotic capsules in 2025?

Probiotic capsules are projected to generate revenues of 1.978 USD Billion in 2025. Read More

How do the revenues for probiotic powders compare to those for probiotic liquids in 2025?

In 2025, probiotic powders are expected to generate 1.368 USD Billion, which is equal to the projected revenue for probiotic liquids. Read More

What is the expected revenue for probiotics targeting elderly patients in 2025?

Probiotics targeting elderly patients are projected to generate revenues of 1.5 USD Billion in 2025. Read More

Which distribution channel is expected to yield the highest revenue in 2025?

Hospitals are expected to yield the highest revenue in 2025, with projections of 1.978 USD Billion. Read More

What is the anticipated revenue for probiotic yogurt in 2025?

Probiotic yogurt is anticipated to generate revenues of 1.226 USD Billion in 2025. Read More

What are the projected revenues for probiotic products aimed at patients with gastrointestinal disorders in 2025?

Probiotic products aimed at patients with gastrointestinal disorders are projected to generate revenues of 1.526 USD Billion in 2025. Read More

Hospital and Nursing Home Probiotic Market

ID: MRFR/FnB/30179-HCR

128 Pages

Varsha More

Last Updated: May 15, 2026

Hospital and Nursing Home Probiotic Market Size, Share, Industry Trend & Analysis Research Report By Probiotic Formulation Type (Capsules, Powder, Liquid, Soft Chew, Probiotic Yogurt), By Target Patient Group (Infants, Adults, Elderly, Immunocompromised Patients, Patients with Gastrointestinal Disorders), By Indication (Antibiotic-Associated Diarrhea, Irritable Bowel Syndrome, Clostridium difficile Infection, Inflammatory Bowel Disease, General Gut Health), By Distribution Channel (Hospitals, Nursing Homes, Pharmacies, Online Retail, Healthcare Facilities), By Product Source (Bacterial Strains, Yeast Strains, Synbiotics, Fermented Foods) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035.

Hospital and Nursing Home Probiotic Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Food, Beverages & Nutrition, BY Probiotic Formulation Type (USD Billion)
  1. 4.1.1 Capsules
  2. 4.1.2 Powder
  3. 4.1.3 Liquid
  4. 4.1.4 Soft Chew
  5. 4.1.5 Probiotic Yogurt
2. 4.2 Food, Beverages & Nutrition, BY Target Patient Group (USD Billion)
  1. 4.2.1 Infants
  2. 4.2.2 Adults
  3. 4.2.3 Elderly
  4. 4.2.4 Immunocompromised Patients
  5. 4.2.5 Patients with Gastrointestinal Disorders
3. 4.3 Food, Beverages & Nutrition, BY Indication (USD Billion)
  1. 4.3.1 Antibiotic-Associated Diarrhea
  2. 4.3.2 Irritable Bowel Syndrome
  3. 4.3.3 Clostridium difficile Infection
  4. 4.3.4 Inflammatory Bowel Disease
  5. 4.3.5 General Gut Health
4. 4.4 Food, Beverages & Nutrition, BY Distribution Channel (USD Billion)
  1. 4.4.1 Hospitals
  2. 4.4.2 Nursing Homes
  3. 4.4.3 Pharmacies
  4. 4.4.4 Online Retail
  5. 4.4.5 Healthcare Facilities
5. 4.5 Food, Beverages & Nutrition, BY Product Source (USD Billion)
  1. 4.5.1 Bacterial Strains
  2. 4.5.2 Yeast Strains
  3. 4.5.3 Synbiotics
  4. 4.5.4 Fermented Foods
6. 4.6 Food, Beverages & Nutrition, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Danone (FR)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Nestle (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Procter & Gamble (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Kerry Group (IE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Chr. Hansen (DK)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Lactalis Ingredients (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Synlogic (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 BioCare Copenhagen (DK)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 ProbioFerm (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
4. 6.4 US MARKET ANALYSIS BY TARGET PATIENT GROUP
5. 6.5 US MARKET ANALYSIS BY INDICATION
6. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
7. 6.7 US MARKET ANALYSIS BY PRODUCT SOURCE
8. 6.8 CANADA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
9. 6.9 CANADA MARKET ANALYSIS BY TARGET PATIENT GROUP
10. 6.10 CANADA MARKET ANALYSIS BY INDICATION
11. 6.11 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
12. 6.12 CANADA MARKET ANALYSIS BY PRODUCT SOURCE
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY TARGET PATIENT GROUP
16. 6.16 GERMANY MARKET ANALYSIS BY INDICATION
17. 6.17 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
18. 6.18 GERMANY MARKET ANALYSIS BY PRODUCT SOURCE
19. 6.19 UK MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
20. 6.20 UK MARKET ANALYSIS BY TARGET PATIENT GROUP
21. 6.21 UK MARKET ANALYSIS BY INDICATION
22. 6.22 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
23. 6.23 UK MARKET ANALYSIS BY PRODUCT SOURCE
24. 6.24 FRANCE MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY TARGET PATIENT GROUP
26. 6.26 FRANCE MARKET ANALYSIS BY INDICATION
27. 6.27 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
28. 6.28 FRANCE MARKET ANALYSIS BY PRODUCT SOURCE
29. 6.29 RUSSIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY TARGET PATIENT GROUP
31. 6.31 RUSSIA MARKET ANALYSIS BY INDICATION
32. 6.32 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
33. 6.33 RUSSIA MARKET ANALYSIS BY PRODUCT SOURCE
34. 6.34 ITALY MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
35. 6.35 ITALY MARKET ANALYSIS BY TARGET PATIENT GROUP
36. 6.36 ITALY MARKET ANALYSIS BY INDICATION
37. 6.37 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
38. 6.38 ITALY MARKET ANALYSIS BY PRODUCT SOURCE
39. 6.39 SPAIN MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY TARGET PATIENT GROUP
41. 6.41 SPAIN MARKET ANALYSIS BY INDICATION
42. 6.42 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
43. 6.43 SPAIN MARKET ANALYSIS BY PRODUCT SOURCE
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY TARGET PATIENT GROUP
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY INDICATION
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY PRODUCT SOURCE
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
51. 6.51 CHINA MARKET ANALYSIS BY TARGET PATIENT GROUP
52. 6.52 CHINA MARKET ANALYSIS BY INDICATION
53. 6.53 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
54. 6.54 CHINA MARKET ANALYSIS BY PRODUCT SOURCE
55. 6.55 INDIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
56. 6.56 INDIA MARKET ANALYSIS BY TARGET PATIENT GROUP
57. 6.57 INDIA MARKET ANALYSIS BY INDICATION
58. 6.58 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
59. 6.59 INDIA MARKET ANALYSIS BY PRODUCT SOURCE
60. 6.60 JAPAN MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY TARGET PATIENT GROUP
62. 6.62 JAPAN MARKET ANALYSIS BY INDICATION
63. 6.63 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
64. 6.64 JAPAN MARKET ANALYSIS BY PRODUCT SOURCE
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY TARGET PATIENT GROUP
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY INDICATION
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY PRODUCT SOURCE
70. 6.70 MALAYSIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY TARGET PATIENT GROUP
72. 6.72 MALAYSIA MARKET ANALYSIS BY INDICATION
73. 6.73 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
74. 6.74 MALAYSIA MARKET ANALYSIS BY PRODUCT SOURCE
75. 6.75 THAILAND MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY TARGET PATIENT GROUP
77. 6.77 THAILAND MARKET ANALYSIS BY INDICATION
78. 6.78 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
79. 6.79 THAILAND MARKET ANALYSIS BY PRODUCT SOURCE
80. 6.80 INDONESIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY TARGET PATIENT GROUP
82. 6.82 INDONESIA MARKET ANALYSIS BY INDICATION
83. 6.83 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
84. 6.84 INDONESIA MARKET ANALYSIS BY PRODUCT SOURCE
85. 6.85 REST OF APAC MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY TARGET PATIENT GROUP
87. 6.87 REST OF APAC MARKET ANALYSIS BY INDICATION
88. 6.88 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
89. 6.89 REST OF APAC MARKET ANALYSIS BY PRODUCT SOURCE
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY TARGET PATIENT GROUP
93. 6.93 BRAZIL MARKET ANALYSIS BY INDICATION
94. 6.94 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
95. 6.95 BRAZIL MARKET ANALYSIS BY PRODUCT SOURCE
96. 6.96 MEXICO MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY TARGET PATIENT GROUP
98. 6.98 MEXICO MARKET ANALYSIS BY INDICATION
99. 6.99 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
100. 6.100 MEXICO MARKET ANALYSIS BY PRODUCT SOURCE
101. 6.101 ARGENTINA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY TARGET PATIENT GROUP
103. 6.103 ARGENTINA MARKET ANALYSIS BY INDICATION
104. 6.104 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
105. 6.105 ARGENTINA MARKET ANALYSIS BY PRODUCT SOURCE
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET PATIENT GROUP
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT SOURCE
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY TARGET PATIENT GROUP
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT SOURCE
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY TARGET PATIENT GROUP
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT SOURCE
122. 6.122 REST OF MEA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY TARGET PATIENT GROUP
124. 6.124 REST OF MEA MARKET ANALYSIS BY INDICATION
125. 6.125 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
126. 6.126 REST OF MEA MARKET ANALYSIS BY PRODUCT SOURCE
127. 6.127 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
130. 6.130 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
131. 6.131 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
132. 6.132 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
133. 6.133 FOOD, BEVERAGES & NUTRITION, BY PROBIOTIC FORMULATION TYPE, 2024 (% SHARE)
134. 6.134 FOOD, BEVERAGES & NUTRITION, BY PROBIOTIC FORMULATION TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 FOOD, BEVERAGES & NUTRITION, BY TARGET PATIENT GROUP, 2024 (% SHARE)
136. 6.136 FOOD, BEVERAGES & NUTRITION, BY TARGET PATIENT GROUP, 2024 TO 2035 (USD Billion)
137. 6.137 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE)
138. 6.138 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Billion)
139. 6.139 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
140. 6.140 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
141. 6.141 FOOD, BEVERAGES & NUTRITION, BY PRODUCT SOURCE, 2024 (% SHARE)
142. 6.142 FOOD, BEVERAGES & NUTRITION, BY PRODUCT SOURCE, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.2.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.3.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.4.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.5.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.6.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.7.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.8.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.9.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.10.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.11.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.12.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.13.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.14.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.15.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.16.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.17.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.18.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.19.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.20.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.21.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.22.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.23.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.24.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.25.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.26.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.27.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.28.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.29.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion)
  3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion)
  4. 7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  5. 7.30.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Food, Beverages & Nutrition Market Segmentation

Food, Beverages & Nutrition By Probiotic Formulation Type (USD Billion, 2025-2035)

Capsules
Powder
Liquid
Soft Chew
Probiotic Yogurt

Food, Beverages & Nutrition By Target Patient Group (USD Billion, 2025-2035)

Infants
Adults
Elderly
Immunocompromised Patients
Patients with Gastrointestinal Disorders

Food, Beverages & Nutrition By Indication (USD Billion, 2025-2035)

Antibiotic-Associated Diarrhea
Irritable Bowel Syndrome
Clostridium difficile Infection
Inflammatory Bowel Disease
General Gut Health

Food, Beverages & Nutrition By Distribution Channel (USD Billion, 2025-2035)

Hospitals
Nursing Homes
Pharmacies
Online Retail
Healthcare Facilities

Food, Beverages & Nutrition By Product Source (USD Billion, 2025-2035)

Bacterial Strains
Yeast Strains
Synbiotics
Fermented Foods

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”